A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors (NCT06336148) | Clinical Trial Compass
TerminatedPhase 1
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Stopped: Sponsor's strategic business decision
United States, Australia10 participantsStarted 2024-06-05
Plain-language summary
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Advanced solid tumor for which there is no remaining standard curative therapy and no therapy with a demonstrated survival benefit, or they must be ineligible to receive or refuse to receive such therapy
✓. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST ) v1.1; amenable for biopsy, and radiographically apparent on computed tomography (CT) or magnetic resonance imaging (MRI )
✓. Eastern Cooperative Oncology Group (ECOG) 0-1
✓. Adequate hematologic, hepatic, pulmonary, and cardiac function
✓. CD4 count \>500/mL at screening
✓. Additional protocol defined inclusion criteria may apply
Exclusion criteria
✕. Active autoimmune disease requiring systemic treatment (i.e., with use of disease modifying agents, systemic corticosteroids or immunosuppressive drug) within the past 6 months prior to dosing of investigational product.
✕. History of permanent artificial implants (e.g., prosthetic joints, artificial heart valves, pacemakers, orthopaedic screw\[s\], metal plate\[s\], bone graft\[s\], or other exogenous implant\[s\]
✕. Known history of cholelithiasis or urolithiasis
✕. History of valvular disease, arterial aneurisms or arterial or venous malformation
✕. Known active brain metastases
What they're measuring
1
Incidence and severity of adverse events and serious adverse events - Part 1a
Timeframe: 1 year
2
Proportion of participants experiencing dose limiting toxicities - Part 1a